Literature DB >> 24421829

Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review.

Alena Tse-Chang1, Dennis Kunimoto2, Evelina Der3, Rabia Ahmed2.   

Abstract

Linezolid is a potentially effective drug for the treatment of patients with drug-resistant tuberculosis. Among 13 patients treated for tuberculosis with linezolid in the present study, nine had treatment success and four remain on treatment. Adverse effects occurred in 11 (85%) patients, of whom three discontinued treatment because of adverse effects. The present study adds to the growing evidence supporting the efficacy of linezolid for tuberculosis, although treatment remains complicated by adverse effects.

Entities:  

Keywords:  Drug-resistant TB; Linezolid; Toxicity; Treatment outcomes

Year:  2013        PMID： 24421829      PMCID： PMC3852456          DOI： 10.1155/2013/535616

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


  17 in total

1.  Linezolid in the treatment of MDR-TB: a retrospective clinical study.

Authors:  H-B Xu; R-H Jiang; L Li; H-P Xiao
Journal:  Int J Tuberc Lung Dis       Date:  2012       Impact factor: 2.373

2.  Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis.

Authors:  W W Yew; C H Chau; K H Wen
Journal:  Int J Tuberc Lung Dis       Date:  2008-03       Impact factor: 2.373

3.  Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.

Authors:  Hae-Seong Nam; Won-Jung Koh; O Jung Kwon; Sang-Nae Cho; Tae Sun Shim
Journal:  Int J Antimicrob Agents       Date:  2008-09-11       Impact factor: 5.283

4.  Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.

Authors:  Bent von der Lippe; Per Sandven; Oddbjørn Brubakk
Journal:  J Infect       Date:  2006-02       Impact factor: 6.072

5.  Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.

Authors:  I-Nae Park; Sang-Bum Hong; Yeon-Mok Oh; Mi-Na Kim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Dong Soon Kim; Won Dong Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2006-07-19       Impact factor: 5.790

6.  Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

Authors:  Holly A Anger; Felicia Dworkin; Saarika Sharma; Sonal S Munsiff; Diana M Nilsen; Shama D Ahuja
Journal:  J Antimicrob Chemother       Date:  2010-02-11       Impact factor: 5.790

Review 7.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Authors:  Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Jan-William C Alffenaar; Holly A Anger; Jose A Caminero; Paolo Castiglia; Saverio De Lorenzo; Giovanni Ferrara; Won-Jung Koh; Giesela F Schecter; Tae S Shim; Rupak Singla; Alena Skrahina; Antonio Spanevello; Zarir F Udwadia; Miquel Villar; Elisabetta Zampogna; Jean-Pierre Zellweger; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-04-10       Impact factor: 16.671

Review 8.  Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  H Cox; N Ford
Journal:  Int J Tuberc Lung Dis       Date:  2012-04       Impact factor: 2.373

9.  A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Authors:  G B Migliori; B Eker; M D Richardson; G Sotgiu; J-P Zellweger; A Skrahina; J Ortmann; E Girardi; H Hoffmann; G Besozzi; N Bevilacqua; D Kirsten; R Centis; C Lange
Journal:  Eur Respir J       Date:  2009-03-12       Impact factor: 16.671

Review 10.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071
View more
  4 in total

1.  Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.

Authors:  Kristina M Bigelow; Amelia N Deitchman; Si-Yang Li; Kala Barnes-Boyle; Sandeep Tyagi; Heena Soni; Kelly E Dooley; Rada M Savic; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2021-06-04       Impact factor: 5.226

2.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

Review 3.  Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.

Authors:  Akosua Adom Agyeman; Richard Ofori-Asenso
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-06-22       Impact factor: 3.944

Review 4.  Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria.

Authors:  Amaylia Oehadian; Prayudi Santoso; Dick Menzies; Rovina Ruslami
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-01-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.